Funding for this research was provided by:
Takeda Science Foundation
Japan Agency for Medical Research and Development (15ck0106012h0002, 15ck0106117h0002)
Core Research for Evolutional Science and Technology (14531766)
National Cancer Center Research and Development Funds (27-A-1, 26-A-3, 25-A-6, 24-A-1)
Received: 7 September 2017
Accepted: 7 May 2018
First Online: 7 June 2018
Ethics approval and consent to participate
: The study was approved by the Institutional Review Boards of the National Cancer Center. All the patients provided written informed consent for the gene analysis and the patients consented to participate in the study. Research was conducted in accordance with the principles of the Declaration of Helsinki.
: NY received grants from Astellas, Bayer, Boehringer Ingelheim, Chugai, Daiichi-Sankyo, Eisai, Kyowa-Hakko Kirin, Lilly Japan, Novartis, Pfizer, Quintiles, Taiho, and Takeda, and honoraria from AstraZeneca, BMS, Chugai, Lilly Japan, Ono, and Pfizer. The remaining authors declare that they have no competing interests.